查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1632660

全球免疫疗法药物市场：市场规模、份额和趋势分析（按药物类型、适应症和地区）、按细分市场预测（2025-2030 年）

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

免疫疗法市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，全球免疫疗法市场规模预计到 2030 年将达到 5,772 亿美元，2025 年至 2030 年的复合年增长率为 13.6%。

推动该产业丰厚成长的关键因素包括人们对癌症、自体免疫疾病、发炎性疾病和感染疾病等慢性疾病的认识不断提高，以及政府对药品核准的支持政策。标靶治疗在治疗慢性病方面的应用日益广泛，这引发了人们对免疫疗法药物的兴趣，预计将在预测期内推动该行业的发展。

例如，2022年5月，Astra Zeneca和第一三共的Enhertu（曲妥珠单抗）在美国获得核准，用于治疗HER2阳性乳癌。其他标靶免疫治疗药物包括Kadcyla (曲妥珠单抗 emtansine) 和TECENTRIQ (Atezolizumab)。 2022 年 6 月，罗氏公司获得欧盟核准将TECENTRIQ用于 NSCLC 的辅助治疗。此外，中低收入国家的医疗保健基础设施发展以及主要企业加强研发力度预计将促进该产业的发展。例如，2021年12月，诺华公司与百济神州有限公司合作研发osiperlimab (BGB-A1217)，扩大了其免疫肿瘤学研发活动。

2021年8月，辉瑞宣布了治疗斑秃的药物利脱髮症替尼2b/3期临床试验的积极结果。此外，全球癌症发生率的增加预计将推动对免疫疗法药物的需求。据Globocan报道，预计2020年将诊断出1,930万例新癌症病例。此外，根据欧洲肿瘤内科学会的数据，预计2020年至2040年间欧洲癌症发生率将增加21%。因此，各种用于治疗癌症的免疫疗法药物的核准预计将促进该行业的成长。

免疫疗法市场：概览

  • 2024 年单株抗体领域占有最大份额，为 76.2%。这一增长得益于治疗性单株抗体研发的增加和政府的支持措施。
  • 这一增长归因于对心血管疾病、呼吸系统疾病和自体免疫疾病等各种慢性疾病的生技药品治疗的高需求。
  • 由于全球癌症发生率的增加以及中低收入国家医疗保健基础设施的改善，肿瘤学领域占据市场主导地位，到 2024 年将占收入的 91.4%。
  • 北美免疫疗法市场占据全球市场主导地位，2024 年的营收份额为 49.9%。
  • 这是由于该地区免疫疗法的采用日益广泛、支持性报销政策以及医疗保健支出不断增加。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章 免疫疗法市场：变数、趋势与范围

  • 市场概况/相关展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 免疫疗法市场：分析工具
    • 波特五力分析
    • PESTEL 分析

第 4 章 免疫治疗药物市场：按药物类型估计和趋势分析

  • 按药物类型分類的市场占有率（2024 年和 2030 年）
  • 药物类型仪表板
  • 依药物类型分類的市场规模预测及趋势分析（2018-2030年）
  • 单株抗体
  • 免疫调节剂
  • 疫苗

第 5 章免疫治疗药物市场：按适应症的估计和趋势分析

  • 各适应症市场占有率（2024 年及 2030 年）
  • 指示仪錶板
  • 市场规模预测及趋势分析（2018-2030）
  • 癌症
  • 自体免疫疾病
  • 感染疾病
  • 其他的

第六章 免疫治疗药物市场：按地区估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与企业概况
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Amgen Inc.
    • Novartis AG
    • AbbVie Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • AstraZeneca
    • GSK plc.
    • Sanofi
    • Bayer AG
Product Code: GVR-4-68039-961-5

Immunotherapy Drugs Market Growth & Trends:

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights:

  • The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
  • The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
  • The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
  • The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
  • This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunotherapy Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 Canada Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 9 Mexico Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 10 Europe Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 11 Europe Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 12 Germany Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 13 UK Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 14 France Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Italy Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 16 Spain Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 17 Sweden Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Denmark Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 19 Norway Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 22 China Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 23 Japan Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 India Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 25 South Korea Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Australia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 28 Latin America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 29 Latin America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Brazil Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 31 Argentina Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 34 South Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 UAE Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Immunotherapy drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Immunotherapy drugs market dynamics
  • Fig. 12 Immunotherapy drugs market: Porter's five forces analysis
  • Fig. 13 Immunotherapy drugs market: PESTLE analysis
  • Fig. 14 Immunotherapy drugs market: Drug type segment dashboard
  • Fig. 15 Immunotherapy drugs market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Monoclonal antibodies market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunomodulator market, 2018 - 2030 (USD Million)
  • Fig. 18 Vaccine market, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy drugs market: Indication segment dashboard
  • Fig. 20 Immunotherapy drugs market: Indication market share analysis, 2024 & 2030
  • Fig. 21 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Autoimmune diseases market, 2018 - 2030 (USD Million)
  • Fig. 23 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunotherapy drugs market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina immunotherapy drugs market, 2018 - 2030 (USD Million
  • Fig. 69 MEA immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework